Mirvie is redefining pregnancy health by developing the first early detection RNA test to address pregnancy complications which impact 45 million women globally
- Pregnancy complications affect 45 million women globally each year, triple the rate of cancer incidence. Today there is no reliable way to identify those pregnancies at-risk.
- The goal of Mirvie’s simple blood test is the early detection of complications such as preterm birth, preeclampsia and gestational diabetes, which has the potential to reduce pregnancy healthcare costs by up to 65%.
- Mirvie is led by a team of pioneers in women’s health, perinatal health, early cancer detection, liquid biopsy and gene sequencing.
SAN FRANCISCO – April 27, 2021 – Mirvie, a pioneer in pregnancy health, today announced it is making rapid progress toward developing a simple, personalized blood test with the potential for early detection of pregnancy complications, such as preterm birth, preeclampsia and gestational diabetes, which affect 1 in 5 women. Currently, there is no reliable way to identify if a mother is at risk for these significant pregnancy complications.